Shed Review: What Its GLP-1 Documentation Establishes—and What It Does Not

The central evidence question about Shed is not whether its website mentions GLP-1 medicines. It clearly does. The harder question is whether a reader can connect a particular product, route, price and care arrangement to the evidence being presented. Shed advertises compounded injections, sublingual products and access to branded medicines, alongside coaching and home delivery. Those are distinct offerings, not interchangeable versions of one clinically established program.

This review examines Shed’s public documentation consulted October 19, 2026, separating documented services from marketing claims and clinical research. The pages establish a substantial telehealth operation, but they also contain conflicting membership fees, inconsistent branded-drug prices and product descriptions that require clarification. The practical aim is to identify what a prospective member can reasonably learn before enrollment—and what still needs a written, product-specific answer.

At a glance

Who provides care: Shed Holdings, LLC operates the platform; its terms assign medical evaluations, prescriptions and follow-up to independent professional entities and their licensed providers.
Sources: [10]
Compounded injection prices: Posted monthly equivalents are $199, $179 and $159 for one-, six- and twelve-month compounded semaglutide plans; compounded tirzepatide is $299, $269 and $239 for the corresponding plans. The tables alone do not establish upfront collection or supply schedules.
Sources: [11] [8]
Branded-price inconsistencies: Wegovy and Zepbound pages contain conflicting $99 and $125 Shed fees and differing medication offers. Medication is separately payable to the dispensing pharmacy under their pricing disclosures.
Sources: [13] [9]
Renewal and cancellation: Medication programs renew automatically, with billing every 28 days or monthly depending on the program. Cancellation requires at least 72 hours’ notice before the next billing date.
Sources: [10]
Evidence boundary: Shed discloses that compounded medications are not FDA approved. Trials of studied injectable medicines do not establish outcomes for Shed, its compounded products or its sublingual offerings.
Sources: [8] [3] [4] [1]

Start with the product, not the GLP-1 label

Shed’s catalog lists compounded semaglutide and compounded tirzepatide as weekly prescription injections. Separate pages promote semaglutide-containing liquid drops and lozenges administered under the tongue. Its branded offerings include a Wegovy page describing a daily pill or weekly pen, subject to approval, and a Zepbound page specifically describing a vial. These distinctions matter: the ingredient name, formulation, route and presentation all belong in the description of what a person is actually considering.

The Foundayo page identifies the product as oral orforglipron and calls it FDA-approved for chronic weight management. That is a provider statement about a product, not an independent regulatory verification or an approval of Shed. The same page uses both “Same active ingredient” and “Same class” comparison language, despite identifying orforglipron and a variable ingredient for injectables. Those statements should not be treated as equivalent claims.

Shed also advertises weight-management options outside this group, including a metformin, naltrexone and topiramate capsule and MIC plus B12 injections. Its broader business covers hair health, sexual wellness and longevity. A long catalog demonstrates advertised availability, not that every option is appropriate or available to every applicant. Our guide to formulation and route differences explains why a familiar ingredient name does not settle the evidence question.

Documented Shed offerings and the distinction to verify
Offering	Public description	Question to resolve
Compounded injections	Semaglutide or tirzepatide; weekly injection	Which exact formulation and dispensing pharmacy apply?
Liquid drops	Semaglutide-containing sublingual formulation	What evidence supports this specific formulation and route?
Lozenges	Semaglutide dissolved under the tongue	Which claims concern the lozenge rather than another product?
Wegovy	Daily pill or weekly pen, if approved	Which presentation and complete price are being offered?
Zepbound	Tirzepatide vial, if approved	Which medication charge and Shed fee control?

Sources: [7] [15] [5] [13] [9] [12] [3] [4]

Clinical research is not a Shed outcomes report

Some compounded-product pages place Wegovy trial references near product-result claims. That proximity does not establish that the advertised preparation produced the trial’s outcomes. STEP 1 studied a specific subcutaneous semaglutide regimen with lifestyle intervention in adults without diabetes; SURMOUNT-1 studied specified subcutaneous tirzepatide regimens in a population also excluding diabetes. Neither was a study of Shed’s care delivery, compounded formulations or sublingual products. Their results cannot be used as a company performance ranking.

Shed describes its drops with “Science-backed results” language and says its lozenges permit steady absorption through the oral mucosa. These remain provider claims in the consulted documentation. The clinical sources available for this review do not establish outcomes for those specific Shed products. A useful evidence request would identify the actual formulation and route, then ask which research studied that product rather than accepting an injectable-drug citation as a substitute.

Compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality. That status alone does not demonstrate clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our explanation of approved medicines and compounded preparations separates that regulatory distinction from claims about effectiveness.

Sources: [15] [5] [8] [11] [3] [4] [1]

The platform and the treating provider are different parties

Although the homepage calls Shed a telehealth clinic, the terms identify Shed Holdings, LLC as the website owner and state that Shed does not practice medicine or provide diagnosis or treatment. Medical evaluations, prescriptions, treatment plans and follow-up schedules belong to independent professional entities and their affiliated licensed healthcare providers. This distinction identifies who is supposed to exercise clinical judgment; it also means the marketing brand is not itself the treating medical practice.

The advertised intake begins with a roughly five-minute form covering health history and preferred administration method. A live visit is not uniformly required or uniformly absent: Shed says the process depends on the state and treatment, with either a virtual encounter or review of an online assessment possible. Its terms require subscribers to be at least 18 and physically located in a U.S. state where the service is available.

Shed says it offers telehealth in all 50 states, while acknowledging treatment restrictions. The terms further tie provider, medicine and synchronous or asynchronous availability to the patient’s physical location during the visit. A Wegovy listing describes adults with BMI of at least 30, or at least 27 with a weight-related condition, but that is not automatic approval. The consulted documentation does not identify the professional entities by legal name or independently establish individual licenses.

Sources: [10] [7] [6]

Compounded-plan prices are clearer than their payment mechanics

The compounded semaglutide injection table lists $199 per month for one month, $179 per month for six months and $159 per month for twelve months. The compounded tirzepatide injection table lists $299, $269 and $239 per month for the corresponding durations. These are documented prices, not a reason to assume the lowest monthly equivalent is available without a longer arrangement. The tables alone do not explain collection timing, shipment quantities or early-exit consequences.

The product-specific drops section starts at $229 per month and explicitly includes medication, supplies, member support and free shipping. The lozenge section describes a month-to-month option starting at $199 per month, with support and free shipping. Both pages also contain Wegovy-related material and lower headline pricing that cannot cleanly be assigned to their sublingual products. The dedicated product sections are therefore more useful than an isolated starting-price headline.

Shed says GLP-1 plan prices do not increase when the provider increases the prescribed amount. That is a commercial pricing claim, not evidence of effectiveness or a complete contract description. The site says insurance is unnecessary and presents programs as access without going through insurance; eligible HSA or FSA cards may cover qualifying services under the applicable plan. Neither statement establishes an individual insurer’s coverage or guarantees account eligibility.

Sources: [11] [8] [15] [5] [7]

Branded-drug pages do not yield one dependable checkout price

Wegovy’s pricing disclosure starts at $149 per month for the pill and $199 per month for the pen for new cash-pay patients, excluding a $99 Shed membership and provider fee. Medication is paid separately to the dispensing pharmacy. Elsewhere, the page lists $349–499 for medication plus $125 per month for membership, without specifying the medication amount’s period in that block. A separate $99-per-month card adds further ambiguity rather than resolving the total.

Zepbound’s specific disclosure starts at $349 per month for new cash-pay patients, plus a separate $99 Shed membership and provider fee, with medication paid to the pharmacy. Another block lists $349–499 for medication plus $125 monthly membership; the opening promotion also shows a $149 starting amount plus $125 membership. These differences affect both the first payment and the continuing charge. Selecting the lowest number would misrepresent the documentation.

Foundayo’s disclosure is more direct: medication starts at $149 per month for new cash-pay patients, excluding a $125 Shed membership and provider fee, and the pharmacy collects medication charges separately. Still, a starting price does not establish every subsequent charge. Before authorizing payment for any branded option, request the exact presentation, first medication payment, later medication payments, Shed fee, billing interval and the identity of each party collecting money.

Sources: [13] [9] [12]

Support is documented, but the channels serve different purposes

Shed’s homepage advertises a dedicated health coach, a dietitian and follow-up appointments as needed. The tirzepatide page promises health coaching, unlimited provider follow-ups and health courses. It also offers free access to Pivot, an app for recording medication administration, side effects, habits and progress. These are identifiable service features, but access promises do not establish how quickly a clinician responds, how often meaningful review occurs or what outcomes members achieve.

The member portal offers routes to the medical provider, nursing support, coaching, educational resources and account or order assistance. Those channels should not be treated as interchangeable. A billing question and a treatment-tolerance question call for different responsibilities. Shed also discloses that free text-based coaching may include automated AI responses, which it says a licensed coach monitors and reviews. That is not the same as a medical consultation with the prescribing clinician.

The terms describe one 15-minute virtual coaching appointment per month for certain memberships and emphasize that medication costs are separate. That narrower benefit should be distinguished from unlimited provider follow-up and text coaching. NIDDK describes medication selection and follow-up as involving health conditions, other medicines, benefits, side effects and response. Our guide to clinical follow-up explains why an available messaging channel is only part of the care arrangement.

Sources: [8] [7] [10] [2]

Pharmacy and delivery claims need a patient-specific answer

Shed says standard shipping is included at no additional cost. Its terms name Strive Compounding Pharmacy, Promise Pharmacy, DCA Pharmacy, Everwell Pharmacy, Custom Ivy Pharmacy and Boothwyn Pharmacy as partners. A partner list does not establish which pharmacy will dispense a particular prescription or independently verify its licensing. Similarly, a pharmacy’s name or a dispensing relationship does not establish that it compounds every medicine available through the platform.

The terms permit transfers among partner pharmacies and do not guarantee a medication’s country of origin. They contemplate shipment from the United Kingdom, Canada or other locations. That qualification deserves attention alongside commercial references to U.S. pharmacies. The consulted pages do not establish a general GLP-1 arrival deadline. A seven-to-ten-business-day estimate after provider approval appears in women’s hair-treatment material and should not be applied to GLP-1 orders.

For an injectable delivery that arrives warm or inadequately refrigerated, FDA explicitly advises not using the product and contacting the provider or dispensing pharmacy. That instruction is more specific than a general reassurance about home shipping. Before purchase, clarify who handles temperature concerns, replacement questions and pharmacy communication. Our guide to delivery and cold-chain claims explains why free shipping, dispatch and satisfactory arrival are separate facts.

Sources: [7] [14] [10] [1]

Renewal can continue even when a shipment does not

Shed’s terms make medication programs automatically renewing subscriptions, billed every 28 days or monthly depending on the program. Four weeks is not a calendar month. Cancellation must occur at least 72 hours before the next billing date; later requests apply to the following month. The stated portal path is “My Treatments,” then “Manage Subscription.” These operational terms matter independently of whether the marketing page describes an attractive monthly equivalent.

Membership fees become nonrefundable once treatment is approved; the terms say the membership fee will be refunded if a licensed provider does not approve treatment. They also state that failure to complete required actions, such as a refill form or required visit, does not make that month refundable when medication is not shipped. A possible one-time future credit is discretionary, requires completing the actions and depends on keeping the subscription active.

The refund policy mentions a two-month minimum commitment, but its application across plans is not clear in the consulted documentation. Multimonth tables likewise do not settle the full cancellation consequences. Shed’s advertised guarantee is conditional on eligibility, check-ins and adherence, not an unconditional refund promise; the complete procedure and refund calculation were unavailable. A useful pre-enrollment document would reconcile the selected plan, commitment, next billing date, patient tasks and guarantee rules in one place.

Sources: [10] [8]

Questions & answers

Does Shed itself prescribe my medication?

Its terms say no: Shed operates the platform, while independent professional entities and their licensed providers deliver medical services. Ask for the treating entity’s name and your clinician’s credentials. The public documentation reviewed here does not identify those entities by legal name or independently verify licenses.

Sources: [10]

Are Shed’s sublingual products supported by the injectable trials?

Those trials do not establish outcomes for Shed’s drops or lozenges. Shed describes semaglutide-containing sublingual products, while STEP 1 studied subcutaneous semaglutide. Ask for evidence addressing the specific formulation and route. Neither a shared ingredient name nor nearby trial marketing establishes the advertised product’s measured results.

Sources: [15] [5] [3]

What should I budget for Shed’s Wegovy or Zepbound?

A reliable total cannot be selected from the conflicting public offers. Both pages separate pharmacy medication payments from Shed fees, but show differing fees and medication amounts. Request a written quote for the precise presentation, new-patient conditions, first payment, renewal charges and billing intervals before authorizing either payment.

Sources: [13] [9]

Will I need a live appointment with Shed?

Possibly. Shed says the evaluation can involve a virtual encounter or an online assessment review, depending on state and treatment. Availability also depends on your physical location during the visit. The five-minute intake estimate is not a promised clinical approval time, and the documentation establishes no general review deadline.

Sources: [7] [10]

Does canceling Shed automatically produce a refund?

No. Cancellation and refund eligibility are separate. The terms require at least 72 hours’ notice before the next charge, make approved-treatment membership fees nonrefundable and describe other refund limitations. They also reference a two-month minimum whose plan-specific scope is unclear. Confirm your selected program’s obligations before enrollment.

Sources: [10]

Who should handle a problem with a Shed delivery?

The portal provides account and order support, and the dispensing pharmacy is another relevant contact. Confirm the pharmacy assigned to your prescription rather than relying on the partner list. If an injectable arrives warm or insufficiently refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy.

Sources: [7] [10] [1]

Our assessment

Shed documents a broad range of prescription options, multiple support channels, home delivery and identifiable subscription rules. Those are meaningful service details, but they are not measured clinical outcomes. The strongest reasons for further clarification are the conflicting branded-drug prices, mixed product descriptions, uncertain multimonth payment mechanics and incomplete guarantee documentation. A prospective member should obtain a product-specific written summary naming the formulation, route, treating entity, pharmacy, complete charges and cancellation obligations. Shed can be evaluated as a documented telehealth access platform; its public materials do not justify transferring injectable-trial results to every product it markets.

Visit Shed’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Shed Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the GLP-1 label

02Clinical research is not a Shed outcomes report

03The platform and the treating provider are different parties

04Compounded-plan prices are clearer than their payment mechanics

05Branded-drug pages do not yield one dependable checkout price

06Support is documented, but the channels serve different purposes

07Pharmacy and delivery claims need a patient-specific answer

08Renewal can continue even when a shipment does not